Loading
Adipokines, Inflammation, and Metabolic Diseases · Journal article
International Journal of Innovative Science and Research Technology · August 11, 2026
Raises a question worth testing. It does not answer one.
This narrative review explores mechanistic links between microbial dysbiosis and obesity, type 2 diabetes, and autoimmunity, emphasizing short-chain fatty acids, lipopolysaccharide-driven inflammation, and the leaky gut hypothesis. The authors acknowledge that while animal models provide insights, large-scale clinical trials are needed before microbiome-targeted therapies can be recommended for clinical practice. No original controlled data are presented to support clinical translation.
Narrative review. Individuals with obesity, type 2 diabetes, and autoimmune disorders; mechanistic discussion also includes animal models..
Fecal Microbiota Transplantation can achieve up to 100% donor engraftment when combined with lifestyle changes, with significant improvements in glycemic markers. Loss of microbial diversity and alterations in the Firmicutes/Bacteroidetes ratio contribute to increased energy harvest and metabolic inflammation. Short-chain fatty acids (butyrate and propionate) modulate insulin sensitivity and appetite regulation.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This review suggests that microbiome-directed interventions may hold therapeutic promise for metabolic and autoimmune diseases, but the authors explicitly state that large-scale clinical trials are essential before translation to clinical practice. Clinicians should treat these mechanistic insights and preliminary FMT findings as hypothesis-generating rather than practice-defining.
This is a narrative review synthesizing existing mechanistic and clinical literature without original data, raising questions about microbiome-targeted interventions rather than answering them with controlled evidence.
As stated by the source record.
Quoted from the source exactly as published.
This review suggests that microbiome-directed interventions may hold therapeutic promise for metabolic and autoimmune diseases, but the authors explicitly state that large-scale clinical trials are essential before translation to clinical practice. Clinicians should treat these mechanistic insights and preliminary FMT findings as hypothesis-generating rather than practice-defining.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
The human microbiome, a complex of microorganisms outnumbering human cells by approximately ten to one, serves as a critical regulator of systemic health. This paper investigates the intricate relationship between microbial dysbiosis and the pathogenesis of obesity, type 2 diabetes (T2DM), and autoimmune disorders. By synthesizing recent metagenomic data and clinical findings, this review explores how the loss of microbial diversity and alterations in the Firmicutes/Bacteroidetes ratio contribute to increased energy harvest and metabolic inflammation. Key results highlight the role of short-chain fatty acids (SCFAs), such as butyrate and propionate, in modulating insulin sensitivity and appetite regulation. Furthermore, the review examines how the 'leaky gut' phenomenon allows lipopolysaccharides (LPS) to trigger chronic systemic inflammation, driving both insulin resistance and autoimmune responses. Specific attention is given to therapeutic interventions; findings indicate that Fecal Microbiota Transplantation (FMT) can achieve up to 100% donor engraftment when combined with lifestyle changes, significantly improving glycemic markers. The study concludes that while animal models provide foundational insights, large-scale clinical trials are essential to transition toward personalized, microbiome-targeted therapies in precision medicine.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.